Literature DB >> 30878022

Role of Epithelial-Mesenchymal Transition in Tumor Progression.

N A Gloushankova1, I Y Zhitnyak2, S N Rubtsova2.   

Abstract

Epithelial-mesenchymal transition (EMT) is a fundamental process of morphogenesis whereby epithelial cells acquire the mesenchymal phenotype. Multiple data suggest a critical role of EMT in tumor progression. In carcinomas, EMT can be initiated and promoted by many oncogenic signaling pathways, hypoxia, and signals of tumor microenvironment resulting in epithelial cells losing their cell polarity and cell-cell adhesion and gaining the migratory and invasive properties. Downregulation of expression of the cell adhesion protein E-cadherin is considered a poor prognostic factor in cancer. Many tumors are characterized by incomplete EMT, where tumor cells acquire mesenchymal characteristics but retain their epithelial markers, in particular, E-cadherin. In cells with the hybrid epithelial-mesenchymal phenotype, E-cadherin is accumulated in adherens junctions which are less stable than adherens junctions in normal epithelial cells. E-cadherin-based adherens junctions are essential for efficient collective migration and invasion of carcinoma cells, and their survival in metastasis. The plasticity of the hybrid epithelial-mesenchymal phenotype improves adaptive capabilities of cancer cells. By undergoing EMT, carcinoma cells become resistant to chemotherapy and acquire the ability to suppress immune response. Emergence of cancer stem cells after EMT activation has been observed in many types of carcinoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30878022     DOI: 10.1134/S0006297918120052

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  29 in total

Review 1.  Stem cell therapy: old challenges and new solutions.

Authors:  Carmela Rita Balistreri; Elena De Falco; Antonella Bordin; Olga Maslova; Alexander Koliada; Alexander Vaiserman
Journal:  Mol Biol Rep       Date:  2020-03-03       Impact factor: 2.316

2.  Silencing of kallikrein-related peptidase 6 attenuates the proliferation, migration, and invasion of gastric cancer cells through inhibition of epithelial-mesenchymal transition.

Authors:  Dong Zhou; Yanping He; Hengping Li; Weidong Huang
Journal:  Exp Ther Med       Date:  2021-05-17       Impact factor: 2.447

3.  Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence.

Authors:  Ekaterini Christina Tampaki; Athanasios Tampakis; Afroditi Nonni; Markus von Flüe; Efstratios Patsouris; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

4.  AURKB Promotes the Metastasis of Gastric Cancer, Possibly by Inducing EMT.

Authors:  Zhen Wang; Zhu Yu; Gong-He Wang; Yi-Ming Zhou; Jian-Ping Deng; Yue Feng; Jun-Qiang Chen; Lei Tian
Journal:  Cancer Manag Res       Date:  2020-08-05       Impact factor: 3.989

5.  Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.

Authors:  Dingyuan Luo; Matthew G Digiovanni; Ran Wei; Joseph F Lacomb; Jennie L Williams; Basil Rigas; Gerardo G Mackenzie
Journal:  Carcinogenesis       Date:  2020-07-14       Impact factor: 4.944

6.  The ionophore antibiotic gramicidin A inhibits pancreatic cancer stem cells associated with CD47 down-regulation.

Authors:  Rui-Qi Wang; Jing Geng; Wei-Jin Sheng; Xiu-Jun Liu; Min Jiang; Yong-Su Zhen
Journal:  Cancer Cell Int       Date:  2019-05-22       Impact factor: 5.722

7.  Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.

Authors:  Ran Wei; Natalia E Cortez Penso; Robert M Hackman; Yuefei Wang; Gerardo G Mackenzie
Journal:  Nutrients       Date:  2019-08-09       Impact factor: 5.717

8.  Wilms' tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1/2 signaling.

Authors:  Yun Han; Chao Song; Tingting Zhang; Qianqian Zhou; Xiaoqian Zhang; Jing Wang; Boqun Xu; Xuesen Zhang; Xiaoqiu Liu; Xiaoyan Ying
Journal:  Cell Cycle       Date:  2020-09-07       Impact factor: 4.534

9.  Correlation between the Expression of Interleukin-6, STAT3, E-Cadherin and N-Cadherin Protein and Invasiveness in Nonfunctional Pituitary Adenomas.

Authors:  Xiaoxu Shen; Qi Liu; Jian Xu; Yang Wang
Journal:  J Neurol Surg B Skull Base       Date:  2019-12-05

10.  Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer.

Authors:  Yuepeng Zhang; Kai Mi; Zhiheng Li; Lixia Qiang; Meiyu Lv; Yushan Wu; Ligong Yuan; Shoude Jin
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.